10x Genomics, Inc. (NASDAQ:TXG) Shares Acquired by Sound Income Strategies LLC

Sound Income Strategies LLC boosted its position in 10x Genomics, Inc. (NASDAQ:TXG) by 65.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,370 shares of the company’s stock after purchasing an additional 1,330 shares during the period. Sound Income Strategies LLC’s holdings in 10x Genomics were worth $48,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. SG Americas Securities LLC grew its stake in shares of 10x Genomics by 209.8% in the 4th quarter. SG Americas Securities LLC now owns 73,046 shares of the company’s stock worth $1,049,000 after purchasing an additional 49,468 shares during the last quarter. Nisa Investment Advisors LLC acquired a new position in 10x Genomics in the fourth quarter worth approximately $237,000. MCF Advisors LLC acquired a new position in 10x Genomics in the fourth quarter worth approximately $92,000. Avanza Fonder AB bought a new position in shares of 10x Genomics in the fourth quarter valued at $945,000. Finally, Mirador Capital Partners LP lifted its position in shares of 10x Genomics by 39.2% during the 4th quarter. Mirador Capital Partners LP now owns 80,983 shares of the company’s stock valued at $1,163,000 after acquiring an additional 22,792 shares during the last quarter. 84.68% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on TXG. Canaccord Genuity Group decreased their target price on 10x Genomics from $32.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, October 10th. Morgan Stanley cut their price objective on 10x Genomics from $30.00 to $28.00 and set an “overweight” rating on the stock in a report on Monday, January 13th. Barclays decreased their target price on shares of 10x Genomics from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Stephens restated an “overweight” rating and set a $30.00 price target on shares of 10x Genomics in a report on Thursday, October 10th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 10x Genomics in a research note on Saturday, January 18th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $23.86.

10x Genomics Price Performance

Shares of NASDAQ TXG opened at $14.81 on Friday. 10x Genomics, Inc. has a one year low of $12.95 and a one year high of $51.22. The business’s 50-day moving average price is $15.02 and its two-hundred day moving average price is $17.84. The company has a market capitalization of $1.79 billion, a P/E ratio of -9.68 and a beta of 1.83.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings results on Tuesday, October 29th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.04. The business had revenue of $151.65 million during the quarter, compared to analysts’ expectations of $158.84 million. 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. The firm’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.51) EPS. On average, equities analysts anticipate that 10x Genomics, Inc. will post -1.43 EPS for the current year.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.